Tuesday 6th June 2023 |
Text too small? |
The a2 Milk Company (a2MC, the Company) notes the announcement from Synlait Milk (Synlait) today confirming it has received approval from China’s State Administration for Market Regulation (SAMR) for the re-registration of a2MC’s China label infant milk formula (IMF) product, 至初® (stages 1, 2 and 3), formulated in line with China’snew GB standards.
SAMR’s approval will allow Synlait to manufacture 至初® for a2MC until September 20271. Production is expected to commence later this month with product transitioning in market during 1H242.
The a2 Milk Company’s Managing Director and CEO, David Bortolussi said:
• “We are pleased to confirm that our China label IMF product re-registration has been approved.
• “We extend our sincere thanks to China’s State Administration for Market Regulation, New Zealand’s Ministry for Primary Industries, our strategic partners in China, CNADC Group and China State Farm Agribusiness, and our manufacturing partner, Synlait and its major shareholder Bright Dairy, for their support throughout the process.
• “We look forward to making our upgraded new China label IMF product available to parents and their infants and young children in China, building on the strong brand loyalty we have developed with Chinese families over the past decade as the pioneer and leader of the A2 protein category.
• “The approval provides a2MC with continued access to China's substantial registered domestic infant milk formula market which remains the key focus of our refreshed growth strategy.”
No comments yet
CHI - Retirement of Director and completion of board refresh
March 20th Morning Report
A return to prosperity depends on capital - General Finance MD
March 19th Morning Report
IPL - Divestment of Woolworths Mount Roskill
AIA - lands new partnership with global duty-free operator
BRW - Board changes & Withdrawal of meeting request
New Zealand King Salmon - Trading Update
GEN - Financial Assistance for the Purchase of Shares
MPG - Metroglass clarifies media statements by Crescent Capital